Shire attempts to defend blood disorder patent

Shire Viropharma has filed a complaint against CSL Behring, a developer of rare disease therapies, for patent infringement.

The case, filed on April 11 at the US District Court for the District of Delaware, alleges that CSL intends to sell Haegarda (C1 esterase inhibitor) which, according to Shire, will infringe its patent.

Issued earlier this month, the patent involved is US number 9,616,111, titled “C1-INH Compositions and Methods for the Prevention and Treatment of Disorders Associated with C1 Esterase Inhibitor Deficiency”.

The patent covers a method for treating a blood disorder known as hereditary angioedema.

According to the complaint, CSL’s Haegarda is expected to launch in June this year.

Shire has asked the court to determine that CSL is infringing the ‘111 patent.

The company has also asked the court for a permanent injunction stopping CSL from bringing its product to the market.

Join us for a FREE webinar— Navigating the CRISPR IP landscape in Europe—on April 25th.

Did you enjoy reading this story?  Sign up to our free newsletter and get stories like this sent straight to your inbox.